Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04630158 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP)
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 153
- Enrollment target
NCT04630158 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 153 participants.
The verdict
NCT04630158, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 153 participants
- Enrollment target
Study Summary
The study was designed to demonstrate the safety and efficacy of two dose concentrations of SAF312 eye drops (5 mg/mL and 15 mg/mL) in subjects with CICP persisting at least for 4 months after refractive or cataract surgery and chronicity confirmed during the observational period. The study also determined the optimal dose to carry forward for further development.
Interventions
- OTHER SAF312 Placebo
- DRUG SAF312
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2021-04-21 |
| Est. Completion | 2023-06-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04630158
The ClinicalTrials.gov registry entry for NCT04630158 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SAF312 Placebo is the first listed.
NCT04630158 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04630158 about?
NCT04630158 is a clinical study titled "Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP)". The study was designed to demonstrate the safety and efficacy of two dose concentrations of SAF312 eye drops (5 mg/mL and 15 mg/mL) in subjects with CICP persisting at least for 4 months after refractive or cataract surgery and chronicity confirmed during the observational period. The study also det...
What is the current status of trial NCT04630158?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 153 participants. The study started on 2021-04-21. Estimated completion is 2023-06-08.
What interventions are being tested in trial NCT04630158?
The interventions under investigation include: SAF312 Placebo (OTHER), SAF312 (DRUG).
Who is sponsoring clinical trial NCT04630158?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.